Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)
Gilead Sciences said Monday it will license Assembly Biosciences’ investigational herpes simplex virus programs, including two oral candidates, for a $35 million payment. The move expands Gilead’s antiviral pipeline days after it joined a Trump administration drug-pricing deal. Shares traded around $123–$124, slightly lower on the day. No new HSV therapies have been approved in the U.S. or Europe for over 25 years.